FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation
Titel:
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation
Auteur:
Zhou, Qing Li, Jie Cang, Shun-Dong Lin, Jia-Xin Tu, Hai-Yan Du, Yingying Qin, Jian-Wen Liang, Xiao-Hua Yu, Yan Lan, Hai-Tao Shi, Hua-Qiu Hua, Dong Liu, Si-Yang Maggie Wu, Yi-Long